Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

#ESMO23 Expert report on amivantamab in combination therapy for 1L treatment in EGFRm, advanced NSCLC

Reporting from ESMO Congress 2023 in Madrid, Nicolas Girard discusses the results from two important studies on amivantamab in combination therapy for first-line treatment of patients with EGFR-mutated, advanced NSCLC

Abstracts discussed:
- LBA14 - Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment in Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From MARIPOSA, a Phase 3, Global, Randomized, Controlled Trial, presented by B.C. Cho

- LBA5 - Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion-mutated Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From PAPILLON, a Randomized Phase 3 Global Study, presented by Nicolas Girard
Simultaneous publication: https://www.nejm.org/doi/full/10.1056/NEJMoa2306441

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.